Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Lucio N Gordan"'
Autor:
Scott S Tykodi, Daniel J George, Jeff Yorio, Lucio N Gordan, Joshua Zhang, Jennifer L Johansen, Arash Rezazadeh Kalebasty, David R Spigel, Samith T Kochuparambil, Ana M Molina, Heidi McKean, Nishan Tchekmedyian, Margarita Askelson, Thomas E Hutson
Publikováno v:
BMJ Open, Vol 12, Iss 9 (2022)
Objectives The non-randomised, open-label, phase IIIb/IV multicohort CheckMate 920 trial explored the safety and efficacy with a less frequent, but continual nivolumab plus ipilimumab (NIVO+IPI) dosing regimen (cohort 1) to determine whether this mod
Externí odkaz:
https://doaj.org/article/a35e5923581b4b07b7b03b97b3b2d842
Autor:
Thomas Hutson, Peter Van Veldhuizen, Michael R Harrison, Scott S Tykodi, Daniel J George, Lucio N Gordan, Robert S Alter, Edward Arrowsmith, Ivor Percent, Rakesh Singal, Joshua Zhang, Jesus Zoco, Jennifer L Johansen, Arash Rezazadeh Kalebasty
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/2afaa38ab63544b783e82c3073c180bf
Autor:
Lucio N. Gordan, David Ray, Stephen C. Ijioma, George Dranitsaris, Amanda Warner, Trevor Heritage, Matthew Fink, David Wenk, Paul Chadwick, Natasha Khrystolubova, Shachar Peles
Publikováno v:
Current Oncology, Vol 31, Iss 1, Pp 501-510 (2024)
Best practice (BP) in cancer care consists of a multifaceted approach comprising individualized treatment plans, evidence-based medicine, the optimal use of supportive care and patient education. We investigated the impact of a BP program in patients
Externí odkaz:
https://doaj.org/article/03fbdb730e0f4021a45793e1fd5c3ec3
Autor:
Bradley Curtis Carthon, Jesus Zoco, Thomas E. Hutson, Mark R. Olsen, Edward Arrowsmith, Johanna C. Bendell, Hamid Emamekhoo, Joshua Zhang, Daniel J. George, Scott S. Tykodi, David Leung, Ana M. Molina, Alexandra Drakaki, Lucio N. Gordan, Ivor John Percent, Daniel C. Cho, Jennifer L. Johansen, Arash Rezazadeh Kalebasty
Publikováno v:
Cancer. 128:966-974
Background Nivolumab plus ipilimumab (NIVO + IPI) has demonstrated long-term efficacy and safety in patients with previously untreated, advanced renal cell carcinoma (aRCC). Although most phase 3 clinical trials exclude patients with brain metastases
Publikováno v:
Future oncology (London, England). 18(3)
Background: The introduction of daratumumab into the treatment of multiple myeloma has improved outcomes in patients; however, community oncologists often dose more frequently than the US FDA-approved label. Materials and methods: Integra analyzed it
Autor:
Daniel J George, David R Spigel, Lucio N Gordan, Samith T Kochuparambil, Ana M Molina, Jeff Yorio, Arash Rezazadeh Kalebasty, Heidi McKean, Nishan Tchekmedyian, Scott S Tykodi, Joshua Zhang, Margarita Askelson, Jennifer L Johansen, Thomas E Hutson
Publikováno v:
BMJ Open. 12:e058396
ObjectivesThe non-randomised, open-label, phase IIIb/IV multicohort CheckMate 920 trial explored the safety and efficacy with a less frequent, but continual nivolumab plus ipilimumab (NIVO+IPI) dosing regimen (cohort 1) to determine whether this modi
Autor:
Robert E. Smith, Melissa Lynne Johnson, Lucio N. Gordan, Mei Xue, Prateesh Varughese, Natalie A. Dorrow, Brandon Wang, Varun Vaidya, Mike Gart, Hinco J. Gierman, Jeffrey A. Scott
Publikováno v:
Journal of Clinical Oncology. 40:1530-1530
1530 Background: In a prior analysis, we identified 525 pts with newly diagnosed NSCLC 4 harboring AOD in the ICD. Of these, 141 were treated prior to the reporting of AOD with chemotherapy (C), immune checkpoint inhibitor (ICI), or both. This report
Autor:
Lucio N. Gordan, Michael Diaz, Anjan Jayantilal Patel, Matthew A. Fink, David Wenk, Alison Roos, Yuqiu Jiang, Janice Tam, Pratheesh Sathyan, Phillip G. Febbo
Publikováno v:
Journal of Clinical Oncology. 40:e21093-e21093
e21093 Background: Molecular testing is an integral part of care for patients with non-small cell lung cancer (NSCLC). Professional guidelines advise broad molecular profiling to identify driver mutations that have either FDA approved therapies or av
Autor:
Mike Gart, Lucio N. Gordan, Rushir J. Choksi, Daniel P. Petro, Jeffrey A. Scott, Prateesh Varughese, Erin Alwon, Robert E. Smith
Publikováno v:
Journal of Clinical Oncology. 40:e13510-e13510
e13510 Background: Broad molecular profile-based initiation of Tx in newly diagnosed NSCLC 4 (KF Mileham, Cancer Med, 2022) is advocated by NCCN guidelines. Despite this, Tx is often started prior to, and without knowledge of, an actionable oncogenic
Autor:
Lucio N. Gordan, Anan Zhou, Nathan Markward, Milena Sullivan, Lance Grady, Ted Okon, Merrill Harmison, Debra A. Patt, Michael Diaz, Jing Peng
Publikováno v:
JCO Clinical Cancer Informatics
PURPOSEWhile the immediate care and access disruptions associated with the COVID-19 pandemic have received growing attention in certain areas, the full range of gaps in cancer screenings and treatment is not yet well understood or well documented thr